Ocunexus Therapeutics

OverviewSuggest Edit

Ocunexus Therapeutics is a biopharmaceutical company developing therapeutics for ophthalmologic diseases. Its technology targets an upstream protein to inhibit the pathological activity of the innate immune system called the inflammasome. The company provides an orally administered treatment for the dry form of age-related macular degeneration and diabetic retinopathy.
TypePrivate
Founded2005
Websiteocunexus.com

Latest Updates

Employees (est.) (Mar 2021)3
Cybersecurity ratingAMore

Key People/Management at Ocunexus Therapeutics

David Pool

David Pool

Chief Financial Officer
James Blair

James Blair

Managing Partner, Domain Associates
Brian Levy

Brian Levy

Chief Executive Officer
Show more

Ocunexus Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2005

Ocunexus Therapeutics total Funding

$59.2 m

Ocunexus Therapeutics latest funding size

$20 m

Time since last funding

9 years ago

Ocunexus Therapeutics investors

Ocunexus Therapeutics's latest funding round in July 2012 was reported to be $20 m. In total, Ocunexus Therapeutics has raised $59.2 m
Show all financial metrics

Ocunexus Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Ocunexus Therapeutics Online and Social Media Presence

Embed Graph

Ocunexus Therapeutics Frequently Asked Questions

  • When was Ocunexus Therapeutics founded?

    Ocunexus Therapeutics was founded in 2005.

  • Who are Ocunexus Therapeutics key executives?

    Ocunexus Therapeutics's key executives are David Pool, James Blair and Brian Levy.

  • How many employees does Ocunexus Therapeutics have?

    Ocunexus Therapeutics has 3 employees.

  • Who are Ocunexus Therapeutics competitors?

    Competitors of Ocunexus Therapeutics include Biogen, MyoKardia and Reata Pharmaceuticals.